SCHEMBL14014128

SCHEMBL14014128

Cc1ccc(NC(=O)Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 3/20 0.66
PSEN2 P49810 3/20 0.66
APH1B Q8WW43 3/20 0.66
NCSTN Q92542 3/20 0.66
APH1A Q96BI3 3/20 0.66
PSENEN Q9NZ42 3/20 0.66
CYP2D6 P10635 1/20 0.66
SMN1; SMN2 Q16637 3/20 0.60
GAA P10253 1/20 0.60
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
MAPT P10636 1/20 0.58
EPHX2 P34913 1/20 0.53
POLB P06746 1/20 0.53
HTT P42858 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
RAB9A P51151 1/20 0.52
MTOR P42345 1/20 0.52
RHOC P08134 1/20 0.51
RHOA P61586 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14038726 0.92 PSEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5470561 0.82 MEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2182551 0.80 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL16542117 0.79 SMN1; SMN2 (0.83) SMN1; SMN2GAAMEN1KMT2AEPHX2
SCHEMBL16786359 0.78 MAPT (0.65) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14014149 0.78 LMNA (0.53) SMN1; SMN2GAAMEN1KMT2AMAPT
SCHEMBL19240308 0.77 SMN1; SMN2 (0.65) SMN1; SMN2GAAMEN1KMT2AMAPT
SCHEMBL16481077 0.75 GAA (0.55) SMN1; SMN2GAAMEN1KMT2AEPHX2
SCHEMBL22758337 0.75 SMN1; SMN2 (0.71) SMN1; SMN2GAAMEN1KMT2AEPHX2
SCHEMBL17183464 0.75 SMN1; SMN2 (1.00) SMN1; SMN2GAAMEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PSEN1 1549/4885PSEN2 3165/4885APH1B 1415/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR PSEN1 2399/4885PSEN2 942/4885APH1B 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.